Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tiscela
- Development stage
- Preclinical
- Lead developer
- Regenicin
- Modality
- Cell Therapies
- Administration
- Topical
01
Overview
Tiscela (formerly known as NovaDerm) is an autologous tissue-engineered cultured skin substitute being developed by Regenicin for the treatment of catastrophic full-thickness burns and chronic wounds. The therapy is prepared by harvesting a small, stamp-sized biopsy of the patient's own skin, from which keratinocytes (epidermal cells) and fibroblasts (dermal cells) are isolated, expanded in vitro, and seeded onto a proprietary collagen scaffold. This bilayered construct mimics natural skin architecture, promoting rapid wound closure and tissue regeneration while minimizing the risk of immune rejection. Tiscela has received Orphan Drug and Humanitarian Use Device (HUD) designations from the FDA.
- Brand names
- NovaDermTiscela
- Other names
- Regenicin Cultured Skin Substitute
Beyond the preview
Go deeper on Tiscela.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tiscela.